PRESENT: Colorectal Cancer Screening Based on Predicted Risk

Sponsor
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland (Other)
Overall Status
Recruiting
CT.gov ID
NCT05357508
Collaborator
(none)
880
1
2
13
67.8

Study Details

Study Description

Brief Summary

Colorectal cancer (CRC) can be effectively prevented by screening. Risk to develop CRC within 15 years is related to increasing age, sex, family history, and lifestyle and, thus, can vary from <1% to >15%.

Fecal immunochemical test (FIT) and colonoscopy are the most widely used screening tests. Colonoscopy is the most accurate test, but is related to risks of bleeding and perforation. Colonoscopy resources are limited, and high uptake of screening colonoscopy for low-risk individuals can cause long wait times for those with CRC symptoms or positive FIT. FIT is less costly can be done at home without preparation and, if done regularly, prevents most CRC mortality, especially in moderate and low-risk individuals. To offer the screening options with a reasonable risk-benefit balance, FIT should be recommended to individuals at low (<3% to develop CRC in 15 years) and moderate (3-6%) risk, and colonoscopy to those at high (>6%) risk.

The primary objective is to study the effect of communicating individual CRC risk score and screening recommendations on appropriate screening uptake at six months in individuals at low, moderate and high risk of developing CRC.

The secondary objectives:
  • Assess the feasibility of a subsequent larger RCT designed to detect a change in clinical outcomes;

  • Explore the impact of psychological factors (perceived susceptibility for CRC, perceived benefits from and barriers to screening) on appropriate screening uptake and participation rates.

The investigators will perform a pilot randomized controlled trial (RCT) of 880 residents from the canton Vaud (Switzerland) aged between 50 and 69 years. The QCancer calculator will be used to calculate the personalized risk score. The participants in the intervention group will receive a brochure with their risk score and appropriate screening recommendations. The participants in the control group will receive the standard brochure of the Vaud CRC screening program, regardless of their risk level. Six months after the intervention, the investigators will measure the proportion of the participants who have undergone appropriate screening. Screening will be considered as appropriate if participants at high risk undertake colonoscopy and participants at low risk undertake FIT. Both tests are appropriate for participants at moderate-risk. The hypothesis is that in the intervention group, individuals will be more likely to undergo screening appropriate to their risk level, whereas the choice of the screening test in the control group will not differ between risk levels.

This study should advance our knowledge of risk-based screening. This may give insights about how to optimize CRC screening programs and offer to the population screening options with a better risk-benefit balance.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Intervention brochure
  • Behavioral: Control brochure
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
880 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Protocol Title: Colorectal Cancer Screening Decisions Based on Predicted Risk: the PREcision ScreENing Randomized Controlled Trial (PRESENT)
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Mar 31, 2023
Anticipated Study Completion Date :
May 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group

Participants in the Intervention group receive a brochure with their personalized risk score for colorectal cancer and screening recommendations (FIT or colonoscopy) corresponding to their risk level.

Behavioral: Intervention brochure
Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.

Active Comparator: Usual care group

Participants in the Usual care group receive the standard brochure designed by the Vaud screening program. This brochure recommends screening to all individuals beginning at age 50 and presents both FIT and colonoscopy as equal options.

Behavioral: Control brochure
Provide participants with general information about options for colorectal cancer screening.

Outcome Measures

Primary Outcome Measures

  1. Self-reported appropriate screening uptake [6-8 months after the intervention]

    Proportion who completed screening test appropriate to risk level. For low risk (<3% 15-yr CRC risk), completing a FIT. For intermediate risk (3-6%15-yr CRC risk), completing a FIT, completing a colonoscopy, or having a colonoscopy appointment. For high risk (>6% 15-yr CRC risk), completing a colonoscopy or having a colonoscopy appointment.

Secondary Outcome Measures

  1. Self-reported overall screening participation [6-8 months after the intervention]

    Proportion who completed any CRC screening test (FIT, colonoscopy, colonoscopy appointment, CT colonography, blood test, etc.

  2. Participation in the randomized trial [6 weeks after mailed invitations]

    Proportion of those invited with completed paper or electronic consent

  3. Eligibility for the Vaud CRC screening program [6 weeks after mailed invitations]

    Proportion of those who returned the baseline questionnaire who are eligible for the Vaud screening program (i.e. not up-to-date with screening, not in colonoscopy surveillance, no personal CRC history, etc.)

  4. Self-reported anxiety [6 weeks after mailed invitations]

    Mean anxiety score using adapted questions from a standardized questionnaire (STAI Fr)

  5. Linkage to Vaud CRC screening program [3-6 months after measurement of primary outcome]

    Proportion of study participants who consent and whose screening status are obtained from the Vaud CRC screening program

  6. Linkage to Vaud tumor registry [6 months to 10 years after measurement of primary outcome]

    Proportion of study participants who consent and whose cancer status are obtained from the Vaud tumor registry. Long time frame chosen given considerable delay in updating the tumor registry and interest in cancer outcomes several years after measurement of primary outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 69 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Aged between 50 and 69;

  • Residents of the Canton of Vaud;

  • Have signed an informed consent (paper or electronic).

Exclusion Criteria:
  • Current CRC symptoms;

  • Personal CRC history;

  • In colonoscopy surveillance for follow-up of high-risk polyp(s);

  • Inflammatory bowel disease;

  • Having done a colonoscopy within 9 years or a FIT within 1,5 years;

  • Planning to leave Switzerland definitively within the next six months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Center for Primary Care and Public Health (Unisante) Lausanne Vaud Switzerland 1011

Sponsors and Collaborators

  • Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Investigators

  • Principal Investigator: Kevin Selby, MD, MAS, Center for Primary Care and Public Health (Unisanté)

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
ClinicalTrials.gov Identifier:
NCT05357508
Other Study ID Numbers:
  • PRESENT STUDY
First Posted:
May 3, 2022
Last Update Posted:
May 19, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 19, 2022